2007/07/18 by Dipankar Seth, Seth, Dipankar, Mritunjay Mandal +12
Agricultural and Biological Sciences · Biochemistry, Genetics and Molecular Biology · #Animal Nutrition and Physiology #Biomolecules (q-bio.BM) #FOS: Biological sciences #Insect and Pesticide Research #Molecular Networks (q-bio.MN) #q-bio.BM #q-bio.MN
paper · pdf · doi:10.48550/arxiv.0707.2659
02 pages, 01 table, 781 words
arxiv created 2007/07/18 · openalex publication_date 2007/07/18 · arxiv updated 2009/12/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28
Wild animals, pets, zoo animals and mammals of veterinary importance heavily suffer from trypanosomiasis. Drugs with serious side effects are currently mainstay of therapies used by veterinarians. Trypanosomiasis is caused by Trypanosoma sp. leading to sleeping sickness in humans. Surface modified (hydrophobic and lipophilic) amorphous nanoporous silica molecules could be effectively used as therapeutic drug for combating trypanosomiasis. The amorphous nanosilica was developed by top-down approach using volcanic soil derived silica (Advasan; 50- 60 nm size with 3-10 nm inner pore size range) and diatomaceous earth (FS; 60-80 nm size with 3-5 nm inner pore size range) as source materials. According to WHO and USDA standards amorphous silica has long been used as feed additives for several veterinary industries and considered to be safe for human consumption. The basic mechanism of action of these nanosilica molecules is mediated by the physical absorption of HDL components in the lipophilic nanopores of nanosilica. This reduces the supply of the host derived cholesterol, thus limiting the growth of the Trypanosoma sp. in vivo.